Genomically-Guided Treatment Trial in Brain Metastases

What's the purpose of the trial?

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
150
Last Updated
5 months ago
Am I Eligible

Participating Centers

There are 348 centers participating in this trial. Enter a location below to find the closet center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Abemaciclib is an experimental therapy being developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
  • Entrectinib is a first generation TRK inhibitor that is used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.
  • Paxalisib is an oral small molecule PI3K/mTOR inhibitor being studied for use in several different cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

CDK Gene Mutation

Accepting patients

PI3K Gene Mutation

Accepting patients

EXPERIMENTAL: Arm I (CDK gene mutation)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(831) 888-0898

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.